Eli Lilly › Eli Lilly (NYSE: LLY) has been a terrific stock to own over the past 15 years; it has consistently outperformed ...

If Lilly secures the full $100 million financial incentive, it would be the single largest award to date under the state’s ...

Eli Lilly (LLY) announced the upcoming retirement of Anne White, a pivotal figure in its neuroscience division, and entered a ...

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Eli Lilly and Company is conducting a ...

Lilly is still worth over $500 billion, but its market capitalisation has shed almost a third in the past year. With ...

Eli Lilly & Co. is tapping the US investment-grade debt market with a deal that’s expected to include a 40-year bond, a ...

Eli Lilly is stepping into rare air. In a bond market where most borrowers are skittish about locking in long-term rates, ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

Eli Lilly beat out its Danish competitor Novo Nordisk for the rights to the experimental drug after a short bidding war, paying just $50mn upfront, according to two people familiar with discussions.